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Abstract It has been hypothesized that dysregulation of brain-
expressed genes is the major predisposing underlying mecha-
nism for autism. This dysregulation may be mediated by differ-
ential methylation of CpG sites within gene promoters, which
could be candidate biomarkers and used for early clinical screen-
ing of autism. A total of 131 pairs of age- and sex-matched
autistic and control subjects were recruited in this study. Periph-
eral blood cells were analyzed. The first five pairs were random-
ly applied to array-based genome-wide methylation studies. A
neuron-specific gene, ENO2, was found to be hypermethylated
in the autistic samples. This difference was validated by bisulfite
sequencing PCR (BSP). The differential expression of ENO2
gene was further analyzed with RT-qPCR and ELISA. The
hypermethylation of ENO2 within the promoter region was
confirmed by BSP to be present in 14.5 % (19/131) of the total
of the autistic samples. The mean ENO2 RNA level in these 19
autistic samples was reduced by about 70 % relative to that in
controls. The average level of ENO2 protein expression in the
19 autistic samples (15.18±3.51 μg/l) was about half of that in
the controls (33.86±8.16 μg/l). Conclusion: These findings
suggest that reduced ENO2 expression may be a biomarker for
a subset of autistic children.
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Introduction
Autism comprises a clinically and genetically heterogeneous
group of disorders with a complex etiology. It is characterized
by impairments in reciprocal social communication and the
presence of restricted, repetitive, and stereotyped patterns of
behavior [5, 31]. It has an early age of onset, typically before
three, and prevalence as high as 1.1 % in the USA [9]. Autism
occurs predominantly in males, with a ratio of males to fe-
males of about 4 to 1. It is a leading cause of childhood
disability and inflicts serious suffering and financial burdens
for the family and the society [4].
Autism has been determined to associate with genetic
deficiencies. Mutations in several genes, such as SHANK3,
NRXN1, NLGN3, NLGN4, and CNTNAPs, encoding synaptic
proteins have been identified to be involved in causing this
disease. Studies have been carried out to identify candidate
biomarker(s) associated with the development of autism.
However, no reliable biomarker to date has yet been found.
Altered immune function and complement system deficiency
have been reported for some children with autism along with a
recurrent incidence of immunological disease [24]. By a pro-
teomic approach, Momeni et al. [14] identified differentially
expressed peptides that were fragments of the C3 complement
protein and could potentially serve as a set of biomarkers for
the early detection of autism. Recent studies [30] found that
differential expression of various synaptic genes may affect
pathways that are responsible for normal brain development.
The differential expression of some of these genes may result
from epigenetic modifications [18].
Autism is largely genetic in origin; however, environmen-
tal factors may play an important role in autism development.
Individual development, especially in the early stages of em-
bryonic development, maternal depression, malnutrition, and
contact of certain chemicals or drugs, can increase the suscep-
tibility of autism [24].
Epigenetics may integrate both genetic and environmental
influences to regulate neurodevelopmental processes in the
etiology of autism [21]. Several genetic syndromes share
features with autism, such as Rett, Fragile X, Prader-Willi,
and Angelman, and demonstrate dysregulation of epigenetic
marks or epigenetic mechanisms [5] (Epigenetic refers to the
heritable regulation of various genetic functions [7]). DNA
methylation is one of the most extensively studied epigenetic
markers. It modulates genomic functions including the regu-
lation of gene differential expression, cellular differentiation,
embryonic development, and genomic imprinting [28]. Due to
its molecular stability, DNA methylation is considered a key
signature of epigenetic changes, and it can be monitored at a
genome-wide level.
Recently, researchers found that the methylation profiling
of DNA extracted from brain tissues of patients with schizo-
phrenia and bipolar disorder had significant changes compar-
ing to normal controls. These changes included hypermethy-
lation regions of suspected gene loci that had formerly been
identified as having a relationship to autism [13]. Interest in
the methyl CpG-binding protein 2 (MECP2) as a global
epigenetic regulator has led to the discovery of increased
methylation of the MECP2 promoter in the frontal cortex of
autistic brains [15]. Certain MECP2 polymorphisms were
associated with an increased risk of autism [16]. Methylation
profiling of lymphoblastoid cell lines from three sets of iden-
tical twins discordant for autism revealed epigenetic differ-
ences and led to the identification of a novel autism candidate
gene, RORA, whose protein product was reduced in autistic
brain samples [17]. Collectively, these studies provide support
for the potential role of DNA methylation in autism. Most
studies of methylation in autism have used brain tissues, but
brain tissue cannot be used for early biomarker detection.
Therefore, we undertook to study the methylation profile of
peripheral lymphocytes from autistic children and their age-
matched controls employing a methylation microchip ap-
proach. We have focused on the hypermethylation and the
differential expression of gene ENO2.
Patients and methods
Study population
A total of 131 pairs of children of age 3 to 12, autism vs.
gender-/age-matched control, were recruited for this study
with a protocol that has been approved by the Ethical Com-
mittee of the Shanghai Children’s Hospital. Written informed
consent was obtained from the parents. All subjects were of
Chinese Han ethnicity. The Children fulfilled the diagnostic
criteria of autism as defined by the Diagnostic and Statistical
Manual of Mental Disorders-IV (DSM-IV) of the American
Psychiatric Association. The diagnosis of autism was made
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based on medical records and interviews by senior psychia-
trists with a consensus obtained using the Mini International
Neuropsychiatric Interview (MINI) instrument [23]. There
were no genetic abnormalities identified in any patients re-
cruited in this study. The control group was recruited from
individuals who received regular developmental check-ups in
the Outpatient Children Healthcare Clinic of Shanghai Chil-
dren’s Hospital whose mental status and history of mental
illness were evaluated by a senior psychiatrist using the in-
strument MINI [23]. Detailed information of the participants
is provided in Table 1.
Preparation of plasma, DNA, RNA, and cDNA
Venous blood was collected into 3-ml EDTA anticoagulant
tubes (Vacutainer System; Becton-Dickinson, Plymouth,
UK), and plasmawas separated immediately by centrifugation
at 1,300g for 10 min at 4 °C, and then stored at −80 °C.
Genomic DNAwas isolated from peripheral leukocytes using
a QIAmp DNA Micro Kit (Qiagen, Darmstadt, Germany),
following the manufacturer’s instructions. Total RNA was
isolated from fresh peripheral blood leukocytes using TRIzol
(Invitrogen, Carlsbad, CA), according to the manufacturer’s
instructions. DNA and RNA concentrations were measured
with a NanoDrop ND-1000 Spectrometer (Thermo Scientific,
Boston, MA). Complementary DNA (cDNA) was prepared
using Reverse Transcriptase M-MLV (RNase H; Takara,
Shiga, Japan).
Methylated DNA immunoprecipitation (MeDIP) array-based
hybridization
In order to screen genome-wide methylation variation,MeDIP
array-based hybridization was carried out. Five pairs of sub-
jects from 131 pairs of autism-control cases were subjected to
MeDIP study (Table 1). Five micrograms of genomic DNA
(gDNA) was sheared to an average length of 200–500 bp with
ultrasound. Autistic gDNAwas incubated with 5 μg of anti-5-
methyl cytidine antibody (Epigentek, New York, NY) but the
control gDNAwas incubated with 5 μg of IgG. The MeDIP-
enriched and input genomic DNA samples were labeled with
Cy5 and Cy3, respectively, and hybridized to a NimbleGen
HG18 CpG Promoter array (Roche NimbleGen, Madison,
WI). MeDIP is a method of high throughput screening of gene
methylation differences. In our study, an antibody specific for
methylated cytosine was used to capture methylated genomic
fragments, which were hybridized against NimbleGen oligo-
nucleotide CpG promoter array that includes 15,936 UCSC-
annotated CpG islands and 17,354 RefSeq gene promoter
regions (covering approximately −1,300 to +500 bp from
the transcription start site). Scanning was performed with an
Axon GenePix 4000B microarray scanner (Molecular De-
vices, Sunnyvale, CA).
Bisulfite sequencing PCR (BSP)
In order to confirm the different methylation status of ENO2
gene identified by MeDIP, bisulfite treatment was performed
using a DNA Methylation Kit (GMS, Reston, VA), following
the manufacturer’s instructions. Bisulfite-treated DNA was
stored at −80 °C until needed.
BSP primers were designed with an online program
MethPrimer (http://www.urogene.org/meth-primer/index1.
html) for Primer F (5′-TGTGAGATATTGAGGTTGTTTTG-
3′) and primer R (5′-ACCCCCRATAAATCAAAAACTA-3′)
to amplify an amplicon with 252 bp, which corresponds to the
region detected by the microarray. The sequence of primers
was blasted against a gene bank in NCBI. In total, 1 μl
bisulfite-modified DNA (50 ng/μl), 2 μl dNTPs (2.5 mM
each), 1 μl of each forward (F) and reverse (R) primer
(10 μM), 1.5 μl MgCl2 (25 mM), 2.5 μl 10×PCR buffer,
and 0.25 μl AmpliTaq polymerase (5 U/μl; Applied
Biosystems, Foster City, CA) were combined in a final vol-
ume of 25μl. Reactions were incubated for 2 min at 94 °C and
then for 35 cycles at 94 °C denaturing for 20 s, 58 °C anneal-
ing for 30 s, and 72 °C extension for 30 s followed by a final
7 min extension at 72 °C. To confirm amplification of the
252 bp product, 10 μl of the completed PCR product was
resolved using a 3 % agarose gel in 1×Tris-borate EDTA and
visualized with ethidium bromide. Bisulfite sequencing PCR
products were sequenced with a DNA analyzer (ABI 3730,
Long Beach, CA) after being cloned into a pMD18-T-vector.
For each sample, 10 colonies were sequenced.
Table 1 Pairs of subjects recruit-
ed in the studies Pairs of subjects Age (years)
Total Male Female ∼3 ∼4 ∼5 ∼6 ∼7 ∼12
MeDIP chip study and validation 5 4 1 2 2 1
Additional BSP of ENO2 126 96 30 9 28 39 17 16 17
RT-qPCR of ENO2 19 14 5 2 2 3 5 3 4
ELISA analysis of ENO2 19 14 5 2 2 3 5 3 4
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Table 2 Differential methylation of genes detected from microchip arrays
Autism vs. control Hypermethylation p value Hypomethylation p value
5 pairs IDUA 0.0008 RTN3 0.0012
HEATR6 0.0009 SLC15A4 0.0013
LASS3 0.0009 PODNL1 0.0015
TOM1L2 0.0012 HECW1 0.0018
LRRC48 0.0013 IDH3G 0.0019
SNORD105B 0.0015 SPSB4 0.0021
ANGPTL6 0.0015
4 pairs (In addition to genes
listed in 5 pairs above)
METAP1 0.0005 TMEM110 0…09
MAP1 0.0005 PCDH10 0.0009
BOLIG3 0.0006 TBC1D9 0.0012
ABCF1 0.0006 AREG 0.0012
BEST2 0.0007 HES3 0.0012
GRIN2 0.0009 PWWP2 0.0013
DKDELR1 0.0009 BCHST3 0.0013
FOXS1 0.0011 MARCH5 0.0013
C20orf149 0.0023 CPEB3 0.0026
ENO2 0.0024 IGSF9B 0.0029
PANX2 0.0025 AP2A2 0.0035
PEAR1 0.0026 F7 0.0038
CCNG2 0.0031 C14orf73 0.0041
BDNF 0.0036 BRMS1L 0.0051
CES2 0.0045 C14orf162 0.0061
FAM96 0.0051 BCL11B 0.0071
BNGEF 0.0062 SOLH 0.0082
FAM19A5 0.0068 C16orf10 0.0081












3 pairs (In addition to genes listed in
5 and 4 pairs above)
NCOA7 0.0004 HIST2H3D 0.0002
TUBB2B 0.0004 RORC 0.0030
CALML3 0.0004 ADAM15 0.0004
PSAP 0.0004 ECE2 0.0005
KCNQ1DN 0.0011 PPP1R2 0.0016
HRAS 0.0015 LYSMD3 0.0017
CDX2 0.0016 RAD50 0.0021
SLC24A2 0.0018 PITX1 0.0029
MLNR 0.0021 IRX1 0.0032
LEO1 0.0026 LOC25845 0.0043
CHRNA3 0.0029
KRT19 0.0031
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RT-qPCR
In order to analyze the expression level of ENO2 gene, one
microgram of total RNA and 20 pmol of real time PCR
downstream primers were used in a 20-μl reverse transcription
reaction with a protocol supplied with a Reverse Transcriptase
M-MLV (RNase H) kit. Quantitative Real Time PCR (RT-
qPCR) was performed on the above RT products. The se-





ATCCACATCTGCTGGAA-3′), and β-actin-Probe (5′-
FAM-ATCAAGATCATTGCTCCTCCTGAGCGC-
TAMRA-3′). In total, 2 μl of each forward (F) and reverse (R)
primer (10 μM), 2 μl MgCl2 (25 mM), 2.5 μl 10×Ex Taq
buffer (Mg2+-free), probe (6.25 μM), 2 μl dNTPs (2.5 mM
each), and 0.25 μl Ex Taq polymerase (5 U/μl; Takara, Shiga,
Japan) were used for a total of 25 μl of solution for the PCR
reactions. The PCR program started at 95 °C for 5 min follow-
ed by 40 cycles of 95 °C for 30 s and 59 °C for 30 s.
Fluorescent Amplisensor marker (FAM) at the wavelength
of 510 nm was collected at 59 °C. The signal was analyzed
by software 2.0.1 installed on the real time PCR apparatus
(ABI 7500, Long Beach, CA). The amplified β-actin gene
was used as an internal control.
Enzyme-linked immunosorbent assay (ELISA)
In order to analyze the expression level of ENO2 protein in
plasma, an ELISA kit (R&D system, Minneapolis, MN) was
used according to the manufacture’s protocol. The optical
density of each well was determined within 30 min with a
microplate reader BioTek synergy 2 (BioTek, Shanghai,
China), which was set to 450 nm.
Statistical analysis
Statistical analyses were performed using the SPSS software
package, version 16.0 (SPSS Inc, Chicago, IL). For microar-
ray data analysis, raw data were extracted as pair files with
NimbleScanTM software. We performed the raw data normal-
ization. The ratio of the methylated to the input signal for each
sequence spotted on the array was adjusted, calculated, and
used for read-out of methylation level by the software. Detec-
tion of peaks with a series of default procedures-specified
parameters was performed to ensure that the differences were
statistically significant (p<0.01). The differentially methylat-
ed genes between the two groups were defined as at least a
1.5-fold change of geometric mean intensity; Student’s t test
was used for methylation percentage and messenger RNA
(mRNA) and protein expression level expression. The stan-
dard deviation (SD) was calculated. A two-tailed p value of
less than 0.05 was considered statistically significant.
Results
Genome-wide DNA methylation pattern of autism
in peripheral blood
There were 228 genes differentially methylated in the promot-
er regions and 247 genes in CpG islands in the five pairs
analyzed by the MeDIP method when 1.5-fold and p<0.05
were pre-set as the cutoff criteria. Compared to the control
group, 7 genes were found to be hypermethylated in the
autistic group from all five pairs. In addition, 19 were
hypermethylated among four pairs and 23 among three pairs.
Compared to the control group, 6 genes were found to be
hypomethylated among all five pairs, 30 among four pairs,
and 10 among three pairs, as shown in Table 2. These genes
were clustered (Fig. 1), and the average linkage clustering was
determined to examine the relationship between genes of
Table 2 (continued)
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synaptic regulation and biological processes using the Pearson
correlation, as shown in Fig. 2.
From Table 2, four genes LASS3, PANX2, SLC15A4, and
ENO2 were selected for further study based on the following
concerns: (1) significant difference of methylation status
among these genes that were identified with MeDIP array in
five pairs of autism-control cases; (2) gene function(s), more
importantly, their potential roles that had been reported previ-
ously in the development of autism [1, 30]; and (3) their
expression in the peripheral blood, which might be a potential
candidate of biomarker for assisting clinical recognition and
early detection of autism.
Validation of hypermethylation of ENO2 gene
The differentially methylated genes LASS3, PANX2,
SLC15A4, and ENO2were verified by BSP with the five pairs
of samples that were used originally for the MeDIP analysis.
We found that SLC15A4, which was hypomethylated in five
out of five pairs byMeDIP, did not reveal hypomethylation by
BSP that is likely a disagreement between the MeDIP and
BSP, as previously reported [19]. The experimental principles
of measuring methylation status with MeDIP array or with
BSP are different. MeDIP was a large-scale purification tech-
nique, which was used to enrich for methylated DNA se-
quences. It consists of isolating methylated DNA fragments
by an antibody raised against 5-methylcytosine. While in BSP
sequencing, cytosine is converted into uracil residue and then
recognized as thymine in subsequent PCR amplification.
However, 5-methylcytosine is resistant to this conversion
and remained as cytosine, allowing methylated cytosine to
be distinguished from unmethylated cytosine. Data is calcu-
lated according to the average probe signals covering the
specific gene in MeDIP array, in which false-positive results
might be emerged. Until now, BSP is the gold standard for the
detection of single-base methylation. Two genes, LASS3 that
was hypermethylated in five out of five byMeDIP and PANX2
in four out of five, did not give a satisfactory PCR amplifica-
tion with a very lowly detectable reverse transcription PCR
(RT-PCR) signal, primers are shown in Supplementary Ta-
ble [1] (online). The genes we selected potentially would be
used as the biomarkers for a subset of autistic children. They
should be expressed in peripheral blood. Considering the
technical performance, RT-PCR would be easier, while BSP
is time consuming. Therefore, we selected RT-PCR as our
platform for validating the differential methylation in periph-
eral blood. If the gene had very lowly detectable RT-PCR
signals that did not give a satisfactory PCR amplification,
we would not go on carrying out BSP. Only the ENO2 gene,
which was hypermethylated in four out of five pairs, was
found to have good PCR amplification, which was consistent
with the outcome of the MeDIP (Fig. 3) and that could be
subjected to further confirmation by BSP sequencing. By this
Fig. 1 Microarray assay
(MeDIP) of genome-wide
differential methylation among
five pairs of autistic (A) and
control (C) DNAs. Cutoff of
cluster aggregation of
differentially methylated genes
was pre-set as 1.5-fold, p<0.05,
and detected by MeDIP in ≥3
pairs of samples. Fifty-one genes
were shown upregulated (red) and
46 downregulated (green)
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approach, the autistic group had an average of 42.51 % of
CpGsmethylated as compared to the control group of 14.24%
(p<0.01; Fig. 3a). Following up on this result, a larger sample
size was tested for hypermethylation of ENO2 that encodes
the isozyme enolase-alpha. Ninety-six pairs of autism vs.
normal control samples were subjected to quantitative BSP
analysis of methylation of the ENO2 gene promoter region.
The original study was performed among 101 pairs (96 pairs
in addition to 5 pairs), in which 16 were found to have
hypermethylation in ENO2 promoter region. To further con-
firm the methylation alteration, an additional set of 30 pairs
was analyzed. In this independent confirmation study, 3 out of
30 (10 %) were shown to have hypermethylation, which gave
a total number of 19 out of 131 pairs (14.5 %) showing
hypermethylation (Fig. 4b). Among the 19 autism-control
pairs of cases, the autistic group had an average of 39.61 %
of CpGs methylated, while the control group had 18.81 %,
showing a significant difference (p<0.01). Within the 19
pairs, 12 were 6 to12 years old, accounting for 9.2 % of the
131 total and 24 % of this age group; 7 were between 3 to
5 years of age, accounting for 5.3 % of the total and 9.2 % of
this age group, as shown in Table 1.
Decreased transcription and translation of ENO2
To investigate whether the hypermethylation of ENO2 found
in our autistic samples resulted in a reduction in gene expres-
sion, we measured mRNA levels by Quantitative RT-PCR
(RT-qPCR) of the ENO2 gene in peripheral blood samples
from the 19 pairs of autism vs. control. As shown in Fig. 5a,
the mean mRNA level of the ENO2 gene in the autistic
samples was significantly lower than in controls, with a
70 % reduction of ENO2 mRNA (p<0.01). ELISA analysis
was used to determine the translational level of the ENO2
protein in these 19 pairs of plasma samples (Fig. 4b). The
average level of ENO2 protein expression in the autistic
samples (15.18±3.51 μg/l) was about half of that in controls
(33.86±8.16 μg/l; p<0.01). However, among 112 pairs that
did not show the hypermethylation difference, there was no
Fig. 2 Network analysis was performed to examine the relationship between the synaptic regulation set of genes and biological processes. Protein-
protein interactions are labeled with blue and protein-DNA interactions with pink
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decreased expression of mRNA or ENO2 protein (p>0.05;
Fig. 5c, d).
The relation between the hypermethylation of ENO2 gene
and environmental factors
The environmental factors including parent, child, and family
characteristics were presented in Table 3. Correlation between
the hypermethylation of ENO2 gene and environmental fac-
tors was further analyzed. We found that compared to the non-
hypermethylation group, the hypermethylation group had a
lower Apgar score at 5 min. In addition, length of breast
feeding and daily TV time both had significant difference
between two groups (Table 4).
Discussion
The number of published studies comparing differences in
blood DNA methylation between cases and controls for com-
plex diseases is increasing. Toperoff et al. found a specific
methylation pattern in whole blood from patients with type 2
diabetes that could be detected prior to the onset of the disease
[29]. It is important to note that cell heterogeneity may act as a
confounder when measuring DNA methylation in whole
blood, and the possibility to adjust for differential cell counts
is being investigated [29]. Differences in DNA methylation
were identified in the leukocytes of mothers of children with
congenital heart defects [2]. In a recent study, adults with
Asperger syndrome were shown to exhibit a sex-specific
expression of serum biomarkers [22]. A proteomic study on
autopsied autism brains using 2-D gel electrophoresis re-
vealed a single-nucleotide polymorphism in glyoxalase [8].
A proteomic study of serum from children with autism also
showed a differential expression of apolipoproteins and com-
ponents of complement [3]. All these studies leave an open
question of whether the differentially expressed proteins are
the result of altered epigenetic methylation.
Our result has demonstrated that hypermethylation of a
single gene, ENO2, may be associated with about 15 % of
autistic cases. Recent studies have identified ENO2 as a gene
involved in the development of autism [30]; differential ex-
pression of the ENO2 gene in the Wernicke area in patients
with schizophrenia [11] and in the anterior cingulated cortex
in female schizophrenia patients [12]. Lastly, a genetic study
reported that several SNP haplotypes of the ENO2 were
associated with schizophrenia [8], suggesting that ENO2
may be involved in the early life. Although it is not defini-
tively sure at present whether hypermethylation ofENO2 gene
is a specific factor to autism and if this epigenetic abnormality
is a part of the epigenetic mechanisms that may result in
autism, or if it is a consequence from other etiological factors,
our finding has opened a new avenue to further investigate the
epigenetic pathogenesis for autism. Although it is not possible
to study directly brain tissues of these patients, the study of
other available tissues would add some clues to support this
hypothesis. Induced pluripotent stem (iPS) cells derived from
autistic patients are being under process to be differentiated to
neuron, which will help to study the methylation status.
The MeDIP results showed that four out of five pairs of
autistic children, 6 to 12 years of age, showed differential
hypermethylation of ENO2. Among 126 additional pairs an-
alyzed with BSP, 15 cases had differential hypermethylation.
Looking into the details on the overall age range of this group
Fig. 3 The hypermethylation of the ENO2 gene in the CpG promoter
microarray. Output of differential methylation of ENO2 gene was obtain-
ed from five pairs of autistic (A) vs. control (C) children. Numbers at the
top of the graphs are the genomic positions
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of 101 children, we noticed that 76 (60%) had an age of 3 to 5,
and 50 (40 %) were 6 to 12 years old. The percentage hyper-
methylation of ENO2 among the younger autistic children
(7/76=9.2 %) was lower than that in the older autistic children
(12/50=24%). Two possible reasons can be suggested for this
difference: either our sample size was too small, due to autism
being a highly heterogeneous complex disease, with many
genes/loci and genetic variations involved, rather than being a
distinct neurodevelopmental disorder [1, 31], or the methyla-
tion of ENO2 gene may have a “time course,” which could be
in agreement with the DNA methylation process associated
with brain development [6]. All 19 children from the group
with ENO2 hypermethylation have significant language
development disorder. They almost have no language spoken
and could not use language to communicate, while the other
112 children had more or less spoken language. Accordingly,
we hypothesize that ENO2 may have a function in language
development.
It has been noticed that the initial methylation study in-
volved five pairs of subjects. The hypermethylation of ENO2
was identified in four out of five pairs (80 %). In the larger
sample studied the propor t ion of pat ients with
hypermethylated ENO2 that was found to be 14 %. Thus,
there is a very significant difference between the pilot study
and the larger study in terms of proportion of abnormal
methylation. Even after correction for age, the proportion
Fig. 4 BSP-sequencing analysis
confirmed the hypermethylation
on these five pairs of DNAs (a).
The filled dark circles denote
methylated cytosine, while the
open circles represent
unmethylated cytosine. To plot
all, 131 pairs of autism vs. control
DNAs (b) show that the gray
squares (autism) are apart from
black circles (control) for the first
set of 19 samples (X-axis #1–19)
but overlapped among the re-
maining 112 samples, which gave
a total of 14.5 % (19/131) of the
autism children with hyperme-
thylation of the ENO2 gene
Fig. 5 Quantitative analysis of
ENO2 gene expression. Both RT-
PCR for mRNA (a) and ELISA
for protein (b) of ENO2 gene
showed significant reduction
(p<0.01) among 19 pairs of au-
tistic vs. control children. Both
RT-PCR for mRNA (c) and
ELISA for protein (d) of ENO2
gene showed no significant dif-
ference among the remaining 112
pairs of autistic vs. control
children
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remains very significantly different (24 % in older pairs with
autistic children vs. controls). To address this discrepancy, our
explanation is that autism is a highly heterogeneous
neurodevelopmental disorder with a complex genetic etiology
and phenotype(s) overlapped with some monogenic genetic
diseases, such as the fragile X syndrome [1], which made the
clinical-diagnosed “autism” as a spectrum of disorders, rather
than a distinct clinical disease. This means that the symptoms
of autism can be present in a variety of combinations with a
range of severity. The disease has variable cognitive manifes-
tations, ranging from a non-verbal child with mental retarda-
tion to a high-functioning college student with above-average
IQ with inadequate social skills. Therefore, it is not surprising
to us to see the discrepancy from clinical point of view. In our
study, the initial five cases subjected to the discovery study
with MeDIP were well characterized as they all have a similar
and typical autistic clinical feature with the characteristic
communication disabilities. However, the remaining larger
set of the cases for confirmation was more heterogeneous.
From the technical point of view, RT-PCR experiments were
carried out manually, but MeDIP was done automatically,
which could be another factor influencing the results. Further
confirmation with well-diagnosed and well-characterized
larger size of autism cases would be necessary to assure that
hypermethylation of ENO2 could be applied as a clinical
biomarker for early detection of autism.
Earlier study on genome-wide methylation identified that
RORA gene was abnormally methylated that resulted in de-
creased expression of RORA protein in peripheral blood [17].
However, our data did not show a replicated result that RORA
gene is hypermethylated at least not in three out of five and
above. Similarly to the above discussion, we believe this is
due to the heterogeneity and the difference of technique
platform.
Elevated plasma levels of ENO2 have been found to be
associated with traumatic brain injury [20] and lung cancer
[26]. Emerging evidence also suggests that ENO2 is associat-
ed with psychiatric disorders. Liao et al. [10] detected 924
differentially expressed gene transcripts using a total gene
expression microarray in lymphoblastoid cell lines between
Table 3 Information of autistic children and their parents
Characteristics Value (%) p value
Autism Control
Maternal characteristics
Age at pregnancy (years)




Housewife 58.4 50.2 0.12
Working mother 41.6 49.8
Education (%)
Tertiary education 36.7 38.2 0.35
Secondary school 39.2 34.3
Primary school 24.1 27.5
Medical history
Caught a cold during the 1st trimester 16.8 14.9
Mental illness 4.9 0
Paternal characteristics
Smoking (%) 60.2 62.1 0.25
Alcohol consumption (%) 74.5 70.1
Mental illness (%) 1.8 0.9
Family characteristics
Monthly income (%)






<37 21.8 11.9 0.04
37–40 68.3 80.2
>40 9.9 7.9
Apgar score at 5 min (%)
8–10 83.2 96.5 0.03
4–7 16.8 3.5
Length of breast feeding
<4 months 21.1 19.7 0.06
4–6 months 42.3 38.9
>6 months 36.6 41.4
Child raised by




<1 h 39.6 50.5 0.04
1–2 h 32.7 29.7
>2 h 27.7 19.8
Medication (%)
Ritalin 20.8 0 0.04
Risperdal 7.9 0
No specific medication 71.3 100
Table 4 Different factors related to the methylation of ENO2 gene









4.72±1.19 7.21±1.91 2.539 0.019
Apgar score
at 5 min
7.12±2.19 9.21±1.83 2.419 0.026
Daily TV
time (h)
2.06±0.82 1.15±0.35 2.149 0.032
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male heroin-dependent individuals and control subjects, and
verified the reduced expression of ENO2 in heroin-dependent
individuals using RT-qPCR and Western blot analysis. It was
reported that reduced expression of ENO2 in heroin-
dependent individuals may confer increased risk for heroin
dependence. Autoantibodies against an epitope conserved in
three isoforms of enolase were detected in the sera of patients
with schizophrenia [25]. Elevated neuronal enolase in the
nucleus accumbency of cocaine overdose victims was also
reported [28]. Moreover, increased ENO2 expression was
detected in the Wernicke area in the postmortem brains of
subjects with schizophrenia [11].
Conclusion
Our findings indicate that downregulation of ENO2 may be
associated with a subset of autism; however, it remains an
open question of whether the ENO2 gene is a key component
in brain development, and if it is differentially expressed in the
embryo or fetal tissues at early stages of gestation. The re-
duced ENO2 expression may be a biomarker for a subset of
autistic children.
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